Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The Janus face of rosiglitazone.

Pich C, Michalik L.

Oncotarget. 2018 Dec 28;9(102):37614-37615. doi: 10.18632/oncotarget.26532. eCollection 2018 Dec 28. No abstract available.

2.

Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.

Pich C, Meylan P, Mastelic-Gavillet B, Nguyen TN, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L.

Cancer Res. 2018 Nov 15;78(22):6447-6461. doi: 10.1158/0008-5472.CAN-18-0912. Epub 2018 Sep 5.

PMID:
30185551
3.

Delayed Hair Follicle Morphogenesis and Hair Follicle Dystrophy in a Lipoatrophy Mouse Model of Pparg Total Deletion.

Sardella C, Winkler C, Quignodon L, Hardman JA, Toffoli B, Giordano Attianese GMP, Hundt JE, Michalik L, Vinson CR, Paus R, Desvergne B, Gilardi F.

J Invest Dermatol. 2018 Mar;138(3):500-510. doi: 10.1016/j.jid.2017.09.024. Epub 2017 Sep 28.

4.

Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation.

Degueurce G, D'Errico I, Pich C, Ibberson M, Schütz F, Montagner A, Sgandurra M, Mury L, Jafari P, Boda A, Meunier J, Rezzonico R, Brembilla NC, Hohl D, Kolios A, Hofbauer G, Xenarios I, Michalik L.

EMBO Mol Med. 2016 Aug 1;8(8):919-36. doi: 10.15252/emmm.201505384. Print 2016 Aug.

5.

Endothelial, but not smooth muscle, peroxisome proliferator-activated receptor β/δ regulates vascular permeability and anaphylaxis.

Wawrzyniak M, Pich C, Gross B, Schütz F, Fleury S, Quemener S, Sgandurra M, Bouchaert E, Moret C, Mury L, Rommens C, Mottaz H, Dombrowicz D, Michalik L.

J Allergy Clin Immunol. 2015 Jun;135(6):1625-35.e5. doi: 10.1016/j.jaci.2014.11.006. Epub 2014 Dec 31.

6.

PPARβ/δ prevents endoplasmic reticulum stress-associated inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism.

Salvadó L, Barroso E, Gómez-Foix AM, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetologia. 2014 Oct;57(10):2126-35. doi: 10.1007/s00125-014-3331-8. Epub 2014 Jul 26.

PMID:
25063273
7.

PPARβ/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells.

Palomer X, Capdevila-Busquets E, Botteri G, Salvadó L, Barroso E, Davidson MM, Michalik L, Wahli W, Vázquez-Carrera M.

Int J Cardiol. 2014 Jun 1;174(1):110-8. doi: 10.1016/j.ijcard.2014.03.176. Epub 2014 Apr 8.

PMID:
24767130
8.

Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer.

Montagner A, Delgado MB, Tallichet-Blanc C, Chan JS, Sng MK, Mottaz H, Degueurce G, Lippi Y, Moret C, Baruchet M, Antsiferova M, Werner S, Hohl D, Saati TA, Farmer PJ, Tan NS, Michalik L, Wahli W.

EMBO Mol Med. 2014 Jan;6(1):80-98.

9.

Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPARβ/δ-null mice.

Barroso E, del Valle J, Porquet D, Vieira Santos AM, Salvadó L, Rodríguez-Rodríguez R, Gutiérrez P, Anglada-Huguet M, Alberch J, Camins A, Palomer X, Pallàs M, Michalik L, Wahli W, Vázquez-Carrera M.

Biochim Biophys Acta. 2013 Aug;1832(8):1241-8. doi: 10.1016/j.bbadis.2013.03.006. Epub 2013 Mar 16.

10.

PPARs at the crossroads of lipid signaling and inflammation.

Wahli W, Michalik L.

Trends Endocrinol Metab. 2012 Jul;23(7):351-63. doi: 10.1016/j.tem.2012.05.001. Epub 2012 Jun 14. Review.

PMID:
22704720
11.

The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.

Serrano-Marco L, Barroso E, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetologia. 2012 Mar;55(3):743-51. doi: 10.1007/s00125-011-2401-4. Epub 2011 Dec 17.

PMID:
22179221
12.

New insights into the role of PPARs.

Montagner A, Rando G, Degueurce G, Leuenberger N, Michalik L, Wahli W.

Prostaglandins Leukot Essent Fatty Acids. 2011 Nov;85(5):235-43. doi: 10.1016/j.plefa.2011.04.016. Epub 2011 Jul 20. Review.

PMID:
21778043
13.

Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes.

Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetes. 2011 Jul;60(7):1990-9. doi: 10.2337/db10-0704. Epub 2011 May 26.

14.

Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism.

Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Rüegg C, Krause KH, Imhof BA.

PLoS One. 2011 Feb 7;6(2):e14665. doi: 10.1371/journal.pone.0014665. Erratum in: PLoS One. 2011;6(2).doi: 10.1371/annotation/a392bbef-b0ec-4c70-b403-74a7bad85178. Imhof, Beat [corrected to Imhof, Beat A].

15.

PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells.

Alvarez-Guardia D, Palomer X, Coll T, Serrano L, Rodríguez-Calvo R, Davidson MM, Merlos M, El Kochairi I, Michalik L, Wahli W, Vázquez-Carrera M.

Biochim Biophys Acta. 2011 Feb;1811(2):59-67. doi: 10.1016/j.bbalip.2010.11.002. Epub 2010 Nov 9.

PMID:
21070867
16.

Nuclear factor I-C links platelet-derived growth factor and transforming growth factor beta1 signaling to skin wound healing progression.

Plasari G, Calabrese A, Dusserre Y, Gronostajski RM, McNair A, Michalik L, Mermod N.

Mol Cell Biol. 2009 Nov;29(22):6006-17. doi: 10.1128/MCB.01921-08. Epub 2009 Sep 14.

17.

Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.

Chong HC, Tan MJ, Philippe V, Tan SH, Tan CK, Ku CW, Goh YY, Wahli W, Michalik L, Tan NS.

J Cell Biol. 2009 Mar 23;184(6):817-31. doi: 10.1083/jcb.200809028.

18.

PPARs Mediate Lipid Signaling in Inflammation and Cancer.

Michalik L, Wahli W.

PPAR Res. 2008;2008:134059. doi: 10.1155/2008/134059. Epub 2008 Dec 21.

19.

Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.

Rodríguez-Calvo R, Serrano L, Coll T, Moullan N, Sánchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetes. 2008 Aug;57(8):2149-57. doi: 10.2337/db08-0176. Epub 2008 Apr 28.

20.

The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.

Tan NS, Icre G, Montagner A, Bordier-ten-Heggeler B, Wahli W, Michalik L.

Mol Cell Biol. 2007 Oct;27(20):7161-75. Epub 2007 Aug 6.

21.

Guiding ligands to nuclear receptors.

Michalik L, Wahli W.

Cell. 2007 May 18;129(4):649-51. Review.

22.

Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease.

Michalik L, Wahli W.

Biochim Biophys Acta. 2007 Aug;1771(8):991-8. Epub 2007 Feb 24. Review.

PMID:
17400022
23.

Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior.

Michalik L, Zoete V, Krey G, Grosdidier A, Gelman L, Chodanowski P, Feige JN, Desvergne B, Wahli W, Michielin O.

J Biol Chem. 2007 Mar 30;282(13):9666-77. Epub 2007 Jan 2.

24.

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.

Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W.

Pharmacol Rev. 2006 Dec;58(4):726-41. Review.

PMID:
17132851
25.
26.

Transcriptional regulation of metabolism.

Desvergne B, Michalik L, Wahli W.

Physiol Rev. 2006 Apr;86(2):465-514. Review.

27.

Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock.

Canaple L, Rambaud J, Dkhissi-Benyahya O, Rayet B, Tan NS, Michalik L, Delaunay F, Wahli W, Laudet V.

Mol Endocrinol. 2006 Aug;20(8):1715-27. Epub 2006 Mar 23.

PMID:
16556735
28.

Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Michalik L, Wahli W.

J Clin Invest. 2006 Mar;116(3):598-606. Review.

29.

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.

Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W.

Prog Lipid Res. 2006 Mar;45(2):120-59. Epub 2006 Jan 25. Review.

PMID:
16476485
30.

PPARs in diseases: control mechanisms of inflammation.

Kostadinova R, Wahli W, Michalik L.

Curr Med Chem. 2005;12(25):2995-3009. Review.

PMID:
16378501
31.

Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.

Di-Poï N, Desvergne B, Michalik L, Wahli W.

J Biol Chem. 2005 Nov 18;280(46):38700-10. Epub 2005 Sep 15.

32.

Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing.

Michalik L, Feige JN, Gelman L, Pedrazzini T, Keller H, Desvergne B, Wahli W.

Mol Endocrinol. 2005 Sep;19(9):2335-48. Epub 2005 May 12.

PMID:
15890673
33.

Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.

Tan NS, Michalik L, Desvergne B, Wahli W.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):99-105. Review.

PMID:
15860251
34.

Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha.

Genolet R, Kersten S, Braissant O, Mandard S, Tan NS, Bucher P, Desvergne B, Michalik L, Wahli W.

J Biol Chem. 2005 Jun 24;280(25):24143-52. Epub 2005 Apr 19.

35.

Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.

Gelman L, Michalik L, Desvergne B, Wahli W.

Curr Opin Cell Biol. 2005 Apr;17(2):216-22. Review. Erratum in: Curr Opin Cell Biol. 2005 Jun;17(3):340.

PMID:
15780600
36.

Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.

Di-Poï N, Michalik L, Desvergne B, Wahli W.

Lipids. 2004 Nov;39(11):1093-9. Review.

PMID:
15726824
37.

Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.

Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M.

Cardiovasc Res. 2005 Mar 1;65(4):832-41.

PMID:
15721863
38.

Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development.

Di-Poï N, Ng CY, Tan NS, Yang Z, Hemmings BA, Desvergne B, Michalik L, Wahli W.

Mol Cell Biol. 2005 Mar;25(5):1696-712.

39.
40.

Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice.

Skrtic S, Carlsson L, Ljungberg A, Lindén D, Michalik L, Wahli W, Oscarsson J.

Liver Int. 2005 Feb;25(1):33-40.

PMID:
15698396
41.

PPARs as drug targets to modulate inflammatory responses?

Genolet R, Wahli W, Michalik L.

Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):361-75. Review.

PMID:
15584886
42.

Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.

Tan NS, Michalik L, Di-Poï N, Ng CY, Mermod N, Roberts AB, Desvergne B, Wahli W.

EMBO J. 2004 Oct 27;23(21):4211-21. Epub 2004 Oct 7.

43.

Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation.

Gremlich S, Nolan C, Roduit R, Burcelin R, Peyot ML, Delghingaro-Augusto V, Desvergne B, Michalik L, Prentki M, Wahli W.

Endocrinology. 2005 Jan;146(1):375-82. Epub 2004 Sep 30.

PMID:
15459119
44.

Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation.

Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, Li M, Metzger D, Chambon PH, Elias PM, Feingold KR.

J Invest Dermatol. 2004 Aug;123(2):305-12.

45.

Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action.

Rieusset J, Seydoux J, Anghel SI, Escher P, Michalik L, Soon Tan N, Metzger D, Chambon P, Wahli W, Desvergne B.

Mol Endocrinol. 2004 Oct;18(10):2363-77. Epub 2004 Jul 1.

PMID:
15231871
46.

Be fit or be sick: peroxisome proliferator-activated receptors are down the road.

Desvergne B, Michalik L, Wahli W.

Mol Endocrinol. 2004 Jun;18(6):1321-32. Epub 2004 Apr 15. Review.

PMID:
15087471
47.

Peroxisome proliferator-activated receptor-beta as a target for wound healing drugs.

Tan NS, Michalik L, Desvergne B, Wahli W.

Expert Opin Ther Targets. 2004 Feb;8(1):39-48. Review.

PMID:
14996617
48.

Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing.

Tan NS, Michalik L, Di-Poï N, Desvergne B, Wahli W.

Biochem Soc Trans. 2004 Feb;32(Pt 1):97-102. Review.

PMID:
14748722
49.

Peroxisome-proliferator-activated receptors and cancers: complex stories.

Michalik L, Desvergne B, Wahli W.

Nat Rev Cancer. 2004 Jan;4(1):61-70. Review. No abstract available.

PMID:
14708026
50.

Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha.

Sanguino E, Ramón M, Michalik L, Wahli W, Alegret M, Sánchez RM, Vázquez-Carrera M, Laguna JC.

Biochem Pharmacol. 2004 Jan 1;67(1):157-66.

PMID:
14667938

Supplemental Content

Loading ...
Support Center